Welcome to our dedicated page for TransCode Therapeutics news (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on TransCode Therapeutics stock.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) is a Boston-based clinical-stage biopharmaceutical company dedicated to combating metastatic disease through the discovery, development, and commercialization of novel microRNA (miRNA) therapeutics. The company's pioneering work centers around its proprietary TTX nanoparticle platform, designed to effectively deliver RNA-based therapies to target and treat various cancers.
The lead therapeutic candidate of TransCode Therapeutics, TTX-MC138, focuses on metastatic tumors that overexpress microRNA-10b, a well-known biomarker associated with metastasis. This candidate is currently undergoing rigorous clinical trials, with initial results indicating promising accumulation of the therapy in metastatic lesions.
The company also boasts a diverse pipeline of RNA therapeutic candidates, including TTX-siPDL1 and TTX-RIGA, aimed at overcoming the delivery challenges of RNA therapies and addressing novel genetic targets relevant to different cancer types. TransCode is actively engaged in expanding its research collaborations, as highlighted by its project combining the TTX platform with Debiopharm’s drug delivery technologies.
However, TransCode faces noteworthy financial and regulatory challenges. Recent communications reveal that the company is addressing compliance issues with Nasdaq listing requirements and the potential need for a reverse stock split to maintain its listing status. Despite these hurdles, TransCode remains committed to advancing its research and development efforts, securing strategic partnerships, and raising sufficient capital to drive its innovative pipeline forward.
TransCode’s vision extends beyond treating metastatic cancer; they aim to revolutionize cancer therapy by creating highly selective treatments that trigger the immune response against tumors while sparing healthy tissues. This approach is exemplified by their tumor-selective RIG-I agonists currently in development.
BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics (Nasdaq: RNAZ) announced its participation at the Chardan 6th Annual Genetic Medicines Conference on October 3-4, 2022. CEO Michael Dudley will present the company's RNA-based innovations aimed at enhancing cancer treatment, including the lead candidate TTX-MC138 focused on metastatic disease, set to enter clinical trials this year. The presentation is scheduled for 1:00 pm ET on October 3 and will be available for live streaming.
TransCode Therapeutics (RNAZ) announced the appointment of Frank J. Slack, PhD, a leader in small noncoding RNA research, to its advisory board. His expertise is anticipated to bolster the company’s mission as it enters clinical development phases with its lead product, TTX-MC138, aimed at treating metastatic cancers responsible for approximately 90% of cancer deaths globally. Slack's background includes pioneering studies on microRNAs, which are crucial for cancer targeting. This strategic addition aligns with upcoming first-in-human studies intended to advance TransCode's innovative RNA therapeutic approaches.
TransCode Therapeutics (NASDAQ: RNAZ) reported its Q2 2022 financial results and business advancements. The company is progressing with its therapeutic programs, aiming to submit an exploratory Investigational New Drug application for TTX-MC138. Notably, it received orphan drug designation for TTX-siPDL1 targeting pancreatic cancer. Cash reserves stood at $13.4 million as of June 30, 2022, down from $20.8 million at the end of 2021, with an operating loss of $4.7 million. A strategic alliance with MD Anderson Cancer Center was also announced to enhance RNA-targeted therapies.
TransCode Therapeutics (Nasdaq: RNAZ) announced a strategic alliance with MD Anderson Cancer Center to enhance its RNA-targeted oncology pipeline. The collaboration focuses on validating therapeutic candidates through preclinical studies, which will aid future clinical trials, including the lead candidate TTX-MC138 aimed at treating metastatic cancers. The partnership aims to leverage MD Anderson's expertise to develop innovative cancer treatment options. TransCode emphasizes its commitment to advancing RNA-based therapies for improved patient outcomes.
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics (NASDAQ: RNAZ) announced the filing of a provisional patent application (US 63/356,449) for a method combining radiotherapy with RNA-based nanoparticles for cancer therapy. The approach aims to activate the immune system by leveraging tumor-derived neoantigens and activating the RIG-I signaling pathway. CEO Michael Dudley emphasized the potential for enhanced cancer treatment through this technology. TransCode is advancing its lead candidate, TTX-MC138, into clinical studies, underscoring its commitment to innovative cancer solutions.
BOSTON, June 09, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics (Nasdaq: RNAZ) announced its attendance and presentation at the BIO International Convention from June 13-16, 2022, in San Diego, CA. CEO Michael Dudley will discuss the company’s RNA-based scientific discoveries that could significantly enhance cancer treatment. He will also outline plans for the lead candidate, TTX-MC138, aimed at treating metastatic disease and progressing to its First-in-Human clinical trial.
TransCode Therapeutics (Nasdaq: RNAZ) has secured a $2.3 million funding from a Fast-Track SBIR grant to continue clinical development of TTX-MC138, its lead candidate for treating advanced solid tumors.
The second tranche of this funding was activated following the achievement of a program milestone in Q1 2022, which contributed $1.1 million to the company. The CEO has confirmed plans to submit an eIND for a first-in-human study this year, aiming to validate the novel delivery platform targeting microRNA-10b, implicated in metastatic disease.
TransCode Therapeutics (Nasdaq: RNAZ) will present at the H.C. Wainwright Global Investment Conference from May 23-26, 2022, with a live presentation scheduled for May 24 at 7:00 a.m. ET. CEO Michael Dudley will highlight the Company’s RNA-based innovations aimed at advancing cancer treatment, including the upcoming First-in-Human trial for its lead candidate, TTX-MC138, planned for late 2022. This candidate targets metastatic disease, responsible for about 90% of cancer deaths globally. The presentation will be available via live feed and on-demand.
TransCode Therapeutics (NASDAQ: RNAZ) has signed an option agreement to negotiate an exclusive license for a radiotheranostic technology aimed at enhancing cancer treatment. Developed by Dr. Zdravka Medarova and her team at Massachusetts General Hospital, this technology involves radiolabeled nanoparticles that could improve diagnostics and therapeutic capabilities. CEO Michael Dudley expressed optimism about integrating this technology with their existing RNA delivery system, TTX. TransCode plans to submit an exploratory IND application to initiate a Phase 0 First-in-Human trial for TTX-MC138 in late 2022.
TransCode Therapeutics (NASDAQ: RNAZ) reported its Q1 2022 financial results, highlighting a cash position of $16.9 million. The company plans to submit an exploratory IND application for its lead candidate, TTX-MC138, in a Phase 0 study targeting advanced solid tumors. Financially, expenses rose significantly, with R&D costing $1.9 million and a total operating loss of $3.5 million. TransCode achieved a milestone in its SBIR grant and aims for further funding to support ongoing projects and team expansions, while also filing for new patents in RNA oncology.
FAQ
What is the current stock price of TransCode Therapeutics (RNAZ)?
What is the market cap of TransCode Therapeutics (RNAZ)?
What does TransCode Therapeutics, Inc. specialize in?
What is TTX-MC138?
What are the challenges TransCode Therapeutics is facing?
What is the significance of the TTX nanoparticle platform?
What recent project involves TransCode’s TTX platform?
What is the clinical status of TTX-MC138?
How does TransCode aim to innovate cancer therapy?
What are some other RNA therapeutic candidates in TransCode’s pipeline?
Who can I contact for more information about TransCode Therapeutics?
What are TransCode’s goals for 2024?
